Releases › ICD-10-PCS FY2022

ICD-10-PCS FY2022

Effective 2021-10-01 to 2022-03-31. 78,227 codes in the release.

205added

62revised

109removed

Codes added 205

Code	Description
00D00ZZ	Extraction of Brain, Open Approach
00D03ZZ	Extraction of Brain, Percutaneous Approach
00D04ZZ	Extraction of Brain, Percutaneous Endoscopic Approach
00D70ZZ	Extraction of Cerebral Hemisphere, Open Approach
00D73ZZ	Extraction of Cerebral Hemisphere, Percutaneous Approach
00D74ZZ	Extraction of Cerebral Hemisphere, Percutaneous Endoscopic Approach
02C03Z7	Extirpation of Matter from Coronary Artery, One Artery, Orbital Atherectomy Technique, Percutaneous Approach
02C13Z7	Extirpation of Matter from Coronary Artery, Two Arteries, Orbital Atherectomy Technique, Percutaneous Approach
02C23Z7	Extirpation of Matter from Coronary Artery, Three Arteries, Orbital Atherectomy Technique, Percutaneous Approach
02C33Z7	Extirpation of Matter from Coronary Artery, Four or More Arteries, Orbital Atherectomy Technique, Percutaneous Approach
02F03ZZ	Fragmentation in Coronary Artery, One Artery, Percutaneous Approach
02F13ZZ	Fragmentation in Coronary Artery, Two Arteries, Percutaneous Approach
02F23ZZ	Fragmentation in Coronary Artery, Three Arteries, Percutaneous Approach
02F33ZZ	Fragmentation in Coronary Artery, Four or More Arteries, Percutaneous Approach
02RA0LZ	Replacement of Heart with Biologic and Synthetic Substitute, Autoregulated Electrohydraulic, Open Approach
02RA0MZ	Replacement of Heart with Synthetic Substitute, Pneumatic, Open Approach
02RH38L	Replacement of Pulmonary Valve with Zooplastic Tissue, In Existing Conduit, Percutaneous Approach
02RH38M	Replacement of Pulmonary Valve with Zooplastic Tissue, Native Site, Percutaneous Approach
02VL0CZ	Restriction of Left Ventricle with Extraluminal Device, Open Approach
02VL0DZ	Restriction of Left Ventricle with Intraluminal Device, Open Approach
02VL0ZZ	Restriction of Left Ventricle, Open Approach
02VL3CZ	Restriction of Left Ventricle with Extraluminal Device, Percutaneous Approach
02VL3DZ	Restriction of Left Ventricle with Intraluminal Device, Percutaneous Approach
02VL3ZZ	Restriction of Left Ventricle, Percutaneous Approach
02VL4CZ	Restriction of Left Ventricle with Extraluminal Device, Percutaneous Endoscopic Approach
02VL4DZ	Restriction of Left Ventricle with Intraluminal Device, Percutaneous Endoscopic Approach
02VL4ZZ	Restriction of Left Ventricle, Percutaneous Endoscopic Approach
03173ZF	Bypass Right Brachial Artery to Lower Arm Vein, Percutaneous Approach
03183ZF	Bypass Left Brachial Artery to Lower Arm Vein, Percutaneous Approach
03FG3Z0	Fragmentation of Intracranial Artery, Percutaneous Approach, Ultrasonic
03FG3ZZ	Fragmentation of Intracranial Artery, Percutaneous Approach
06LY7CC	Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening
06LY7CZ	Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening
06LY7DC	Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening
06LY7DZ	Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening
06LY7ZC	Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening
06LY7ZZ	Occlusion of Lower Vein, Via Natural or Artificial Opening
06LY8CC	Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening Endoscopic
06LY8CZ	Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening Endoscopic
06LY8DC	Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic
06LY8DZ	Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening Endoscopic
06LY8ZC	Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening Endoscopic
06LY8ZZ	Occlusion of Lower Vein, Via Natural or Artificial Opening Endoscopic
07DT0ZX	Extraction of Bone Marrow, Open Approach, Diagnostic
07DT0ZZ	Extraction of Bone Marrow, Open Approach
07DT3ZX	Extraction of Bone Marrow, Percutaneous Approach, Diagnostic
07DT3ZZ	Extraction of Bone Marrow, Percutaneous Approach
0F800ZZ	Division of Liver, Open Approach
0F803ZZ	Division of Liver, Percutaneous Approach
0F804ZZ	Division of Liver, Percutaneous Endoscopic Approach
0F810ZZ	Division of Right Lobe Liver, Open Approach
0F813ZZ	Division of Right Lobe Liver, Percutaneous Approach
0F814ZZ	Division of Right Lobe Liver, Percutaneous Endoscopic Approach
0F820ZZ	Division of Left Lobe Liver, Open Approach
0F823ZZ	Division of Left Lobe Liver, Percutaneous Approach
0F824ZZ	Division of Left Lobe Liver, Percutaneous Endoscopic Approach
0K847ZZ	Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening
0K848ZZ	Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening Endoscopic
0NH003Z	Insertion of Infusion Device into Skull, Open Approach
0NH033Z	Insertion of Infusion Device into Skull, Percutaneous Approach
0NH043Z	Insertion of Infusion Device into Skull, Percutaneous Endoscopic Approach
0PS403Z	Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach
0PS443Z	Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach
0QBN0Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach
0QBN3Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach
0QBN4Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach
0QBP0Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach
0QBP3Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach
0QBP4Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach
0QS003Z	Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach
0QS043Z	Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach
0RPJ0J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Open Approach
0RPJ0J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Open Approach
0RPJ3J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Approach
0RPJ3J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Approach
0RPJ4J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
0RPJ4J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
0RPK0J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Open Approach
0RPK0J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Open Approach
0RPK3J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Approach
0RPK3J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Approach
0RPK4J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
0RPK4J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
0RWJ0J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Open Approach
0RWJ0J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Open Approach
0RWJ3J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Approach
0RWJ3J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Approach
0RWJ4J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
0RWJ4J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
0RWJXJ6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, External Approach
0RWJXJ7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, External Approach
0RWK0J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Open Approach
0RWK0J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Open Approach
0RWK3J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Approach
0RWK3J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Approach
0RWK4J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
0RWK4J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
0RWKXJ6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, External Approach
0RWKXJ7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, External Approach
30233D1	Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Peripheral Vein, Percutaneous Approach
30243D1	Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Central Vein, Percutaneous Approach
3E1M48X	Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach, Diagnostic
3E1M48Z	Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach
4B00XW0	Measurement of Central Nervous Cerebrospinal Fluid Shunt using Wireless Sensor, External Approach
5A1221J	Performance of Cardiac Output, Continuous, Automated
BF150ZZ	Fluoroscopy of Liver using High Osmolar Contrast
BF151ZZ	Fluoroscopy of Liver using Low Osmolar Contrast
BF15YZZ	Fluoroscopy of Liver using Other Contrast
BF15ZZA	Fluoroscopy of Liver, Guidance
X2CP3T7	Extirpation of Matter from Abdominal Aorta using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2CQ3T7	Extirpation of Matter from Right Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2CR3T7	Extirpation of Matter from Left Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2CS3T7	Extirpation of Matter from Right Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2CT3T7	Extirpation of Matter from Left Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2CU3T7	Extirpation of Matter from Right Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2CV3T7	Extirpation of Matter from Left Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2CY3T7	Extirpation of Matter from Great Vessel using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
X2J	New Technology, Cardiovascular System, Inspection
X2JAX47	Inspection of Heart using Transthoracic Echocardiography, Computer-aided Guidance, New Technology Group 7
X2K	New Technology, Cardiovascular System, Bypass
X2KB317	Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
X2KC317	Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
X2RX0N7	Replacement of Thoracic Aorta, Arch using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
X2V	New Technology, Cardiovascular System, Restriction
X2V73Q7	Restriction of Coronary Sinus with Reduction Device, Percutaneous Approach, New Technology Group 7
X2VW0N7	Restriction of Thoracic Aorta, Descending using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
XD2	New Technology, Gastrointestinal System, Monitoring
XD2G4V7	Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
XD2G8V7	Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
XD2H4V7	Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
XD2H8V7	Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
XDP	New Technology, Gastrointestinal System, Irrigation
XDPH8K7	Irrigation of Lower GI using Intraoperative Single-use Oversleeve, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
XFJ	New Technology, Hepatobiliary System and Pancreas, Inspection
XFJB8A7	Inspection of Hepatobiliary Duct using Single-use Duodenoscope, New Technology Group 7
XFJD8A7	Inspection of Pancreatic Duct using Single-use Duodenoscope, New Technology Group 7
XHRPXF7	Replacement of Skin with Bioengineered Allogeneic Construct, External Approach, New Technology Group 7
XNS00C7	Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
XNS03C7	Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
XNS40C7	Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
XNS43C7	Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
XRGA0R7	Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
XRGA3R7	Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGA4R7	Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XRGB0R7	Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
XRGB3R7	Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGB4R7	Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XRGC0R7	Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
XRGC3R7	Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGC4R7	Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XRGD0R7	Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
XRGD3R7	Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
XRGD4R7	Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
XW00X27	Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7
XW01397	Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW013V7	Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW013W7	Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW01X27	Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
XW023V7	Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
XW023W7	Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
XW03357	Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03367	Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03377	Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03387	Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033A7	Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033B7	Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033C7	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033G7	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033J7	Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K7	Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033L7	Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033M7	Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW04357	Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW04367	Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
XW04377	Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
XW04387	Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
XW043A7	Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
XW043B7	Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW043C7	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043G7	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043J7	Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043K7	Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043L7	Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043M7	Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW0DXR7	Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7
XW0G7R7	Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7
XW0H7R7	Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7
XW0V0P7	Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
XW133D7	Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW133E7	Transfusion of Hyperimmune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW143D7	Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
XW143E7	Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
XWH	New Technology, Anatomical Regions, Insertion
XWHD7Q7	Insertion of Neurostimulator Lead into Mouth and Pharynx, Via Natural or Artificial Opening, New Technology Group 7
XXE0X07	Measurement of Intracranial Vascular Activity, Computer-aided Assessment, New Technology Group 7
XXE3X27	Measurement of Pulmonary Artery Flow, Computer-aided Triage and Notification, New Technology Group 7
XXE5XR7	Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7
XXE5XT7	Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7
XXE5XV7	Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7
XXE97U7	Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7
XY0YX37	Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7

Descriptions revised 62

Code	Was, and is now
3E00X0M	~~Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach
3E0130M	~~Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach
3E0230M	~~Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
3E0300M	~~Introduction of Monoclonal Antibody into Peripheral Vein, Open Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach
3E0330M	~~Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach
3E0400M	~~Introduction of Monoclonal Antibody into Central Vein, Open Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach
3E0430M	~~Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach
3E0500M	~~Introduction of Monoclonal Antibody into Peripheral Artery, Open Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach
3E0530M	~~Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach
3E0600M	~~Introduction of Monoclonal Antibody into Central Artery, Open Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
3E0630M	~~Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
3E0930M	~~Introduction of Monoclonal Antibody into Nose, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach
3E0970M	~~Introduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening
3E09X0M	~~Introduction of Monoclonal Antibody into Nose, External Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach
3E0A30M	~~Introduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach
3E0B30M	~~Introduction of Monoclonal Antibody into Ear, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach
3E0B70M	~~Introduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening
3E0BX0M	~~Introduction of Monoclonal Antibody into Ear, External Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach
3E0C30M	~~Introduction of Monoclonal Antibody into Eye, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach
3E0C70M	~~Introduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening
3E0CX0M	~~Introduction of Monoclonal Antibody into Eye, External Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach
3E0D30M	~~Introduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach
3E0D70M	~~Introduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening
3E0DX0M	~~Introduction of Monoclonal Antibody into Mouth and Pharynx, External Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach
3E0E30M	~~Introduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach
3E0E70M	~~Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening
3E0E80M	~~Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic
3E0F30M	~~Introduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach
3E0F70M	~~Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening
3E0F80M	~~Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
3E0G30M	~~Introduction of Monoclonal Antibody into Upper GI, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach
3E0G70M	~~Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening
3E0G80M	~~Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic
3E0H30M	~~Introduction of Monoclonal Antibody into Lower GI, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach
3E0H70M	~~Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening
3E0H80M	~~Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic
3E0J30M	~~Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach
3E0J70M	~~Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
3E0J80M	~~Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
3E0K30M	~~Introduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach
3E0K70M	~~Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening
3E0K80M	~~Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
3E0L30M	~~Introduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach
3E0L70M	~~Introduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening
3E0M30M	~~Introduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach
3E0M70M	~~Introduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening
3E0N30M	~~Introduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach
3E0N70M	~~Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening
3E0N80M	~~Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic
3E0P30M	~~Introduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach
3E0P70M	~~Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening
3E0P80M	~~Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic~~ Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic
3E0Q00M	~~Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Open Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach
3E0Q30M	~~Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach
3E0Q70M	~~Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening
3E0R30M	~~Introduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach
3E0S30M	~~Introduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach
3E0U30M	~~Introduction of Monoclonal Antibody into Joints, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach
3E0V30M	~~Introduction of Monoclonal Antibody into Bones, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach
3E0W30M	~~Introduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach
3E0Y30M	~~Introduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach~~ Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach
3E0Y70M	~~Introduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening~~ Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening

Codes removed 109

Code	Description
30230AZ	Transfusion of Embryonic Stem Cells into Peripheral Vein, Open Approach
30230C0	Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Open Approach
30230G0	Transfusion of Autologous Bone Marrow into Peripheral Vein, Open Approach
30230G2	Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Open Approach
30230G3	Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Open Approach
30230G4	Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Open Approach
30230H0	Transfusion of Autologous Whole Blood into Peripheral Vein, Open Approach
30230H1	Transfusion of Nonautologous Whole Blood into Peripheral Vein, Open Approach
30230J0	Transfusion of Autologous Serum Albumin into Peripheral Vein, Open Approach
30230J1	Transfusion of Nonautologous Serum Albumin into Peripheral Vein, Open Approach
30230K0	Transfusion of Autologous Frozen Plasma into Peripheral Vein, Open Approach
30230K1	Transfusion of Nonautologous Frozen Plasma into Peripheral Vein, Open Approach
30230L0	Transfusion of Autologous Fresh Plasma into Peripheral Vein, Open Approach
30230L1	Transfusion of Nonautologous Fresh Plasma into Peripheral Vein, Open Approach
30230M0	Transfusion of Autologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach
30230M1	Transfusion of Nonautologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach
30230N0	Transfusion of Autologous Red Blood Cells into Peripheral Vein, Open Approach
30230N1	Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach
30230P0	Transfusion of Autologous Frozen Red Cells into Peripheral Vein, Open Approach
30230P1	Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open Approach
30230Q0	Transfusion of Autologous White Cells into Peripheral Vein, Open Approach
30230Q1	Transfusion of Nonautologous White Cells into Peripheral Vein, Open Approach
30230R0	Transfusion of Autologous Platelets into Peripheral Vein, Open Approach
30230R1	Transfusion of Nonautologous Platelets into Peripheral Vein, Open Approach
30230S0	Transfusion of Autologous Globulin into Peripheral Vein, Open Approach
30230S1	Transfusion of Nonautologous Globulin into Peripheral Vein, Open Approach
30230T0	Transfusion of Autologous Fibrinogen into Peripheral Vein, Open Approach
30230T1	Transfusion of Nonautologous Fibrinogen into Peripheral Vein, Open Approach
30230U2	Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
30230U3	Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
30230U4	Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
30230V0	Transfusion of Autologous Antihemophilic Factors into Peripheral Vein, Open Approach
30230V1	Transfusion of Nonautologous Antihemophilic Factors into Peripheral Vein, Open Approach
30230W0	Transfusion of Autologous Factor IX into Peripheral Vein, Open Approach
30230W1	Transfusion of Nonautologous Factor IX into Peripheral Vein, Open Approach
30230X0	Transfusion of Autologous Cord Blood Stem Cells into Peripheral Vein, Open Approach
30230X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Open Approach
30230X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Open Approach
30230X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Open Approach
30230Y0	Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Open Approach
30230Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Open Approach
30230Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Open Approach
30230Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Open Approach
30240AZ	Transfusion of Embryonic Stem Cells into Central Vein, Open Approach
30240C0	Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Open Approach
30240G0	Transfusion of Autologous Bone Marrow into Central Vein, Open Approach
30240G2	Transfusion of Allogeneic Related Bone Marrow into Central Vein, Open Approach
30240G3	Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Open Approach
30240G4	Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Open Approach
30240H0	Transfusion of Autologous Whole Blood into Central Vein, Open Approach
30240H1	Transfusion of Nonautologous Whole Blood into Central Vein, Open Approach
30240J0	Transfusion of Autologous Serum Albumin into Central Vein, Open Approach
30240J1	Transfusion of Nonautologous Serum Albumin into Central Vein, Open Approach
30240K0	Transfusion of Autologous Frozen Plasma into Central Vein, Open Approach
30240K1	Transfusion of Nonautologous Frozen Plasma into Central Vein, Open Approach
30240L0	Transfusion of Autologous Fresh Plasma into Central Vein, Open Approach
30240L1	Transfusion of Nonautologous Fresh Plasma into Central Vein, Open Approach
30240M0	Transfusion of Autologous Plasma Cryoprecipitate into Central Vein, Open Approach
30240M1	Transfusion of Nonautologous Plasma Cryoprecipitate into Central Vein, Open Approach
30240N0	Transfusion of Autologous Red Blood Cells into Central Vein, Open Approach
30240N1	Transfusion of Nonautologous Red Blood Cells into Central Vein, Open Approach
30240P0	Transfusion of Autologous Frozen Red Cells into Central Vein, Open Approach
30240P1	Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open Approach
30240Q0	Transfusion of Autologous White Cells into Central Vein, Open Approach
30240Q1	Transfusion of Nonautologous White Cells into Central Vein, Open Approach
30240R0	Transfusion of Autologous Platelets into Central Vein, Open Approach
30240R1	Transfusion of Nonautologous Platelets into Central Vein, Open Approach
30240S0	Transfusion of Autologous Globulin into Central Vein, Open Approach
30240S1	Transfusion of Nonautologous Globulin into Central Vein, Open Approach
30240T0	Transfusion of Autologous Fibrinogen into Central Vein, Open Approach
30240T1	Transfusion of Nonautologous Fibrinogen into Central Vein, Open Approach
30240U2	Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
30240U3	Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
30240U4	Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
30240V0	Transfusion of Autologous Antihemophilic Factors into Central Vein, Open Approach
30240V1	Transfusion of Nonautologous Antihemophilic Factors into Central Vein, Open Approach
30240W0	Transfusion of Autologous Factor IX into Central Vein, Open Approach
30240W1	Transfusion of Nonautologous Factor IX into Central Vein, Open Approach
30240X0	Transfusion of Autologous Cord Blood Stem Cells into Central Vein, Open Approach
30240X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Open Approach
30240X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Open Approach
30240X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Open Approach
30240Y0	Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Open Approach
30240Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Open Approach
30240Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Open Approach
30240Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Open Approach
30280B1	Transfusion of Nonautologous 4-Factor Prothrombin Complex Concentrate into Vein, Open Approach
X2C0361	Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
X2C1361	Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
X2C2361	Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
X2C3361	Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
XR2	New Technology, Joints, Monitoring
XR2G021	Monitoring of Right Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
XR2H021	Monitoring of Left Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
XW03321	Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW03331	Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW03341	Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW033C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW04321	Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
XW04331	Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1
XW04341	Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
XW04351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1
XW043C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3
XW2	New Technology, Anatomical Regions, Transfusion
XW23346	Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW23376	Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW24346	Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6
XW24376	Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6